Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Pain, Intractable × resiniferatoxin × Clear all

Phase

Status

Withdrawn 1 Suspended 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pain, Intractable 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Cancer Pain 1

Interventions

resiniferatoxin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02522611 2026-01-23

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

National Institutes of Health Clinical Center (CC)

Phase 1/2 Not yet recruiting

Cancer Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon ⚡